Irritable Bowel Syndrome Characterized By Constipation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for irritable bowel syndrome characterized by constipation. 36 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
36
Active US patents
66/100
Avg vulnerability
—
Annual revenue covered

Originators in Irritable Bowel Syndrome Characterized By Constipation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 30 patents Sucampo Pharma Llc 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating irritable bowel syndrome characterized by constipation. Each bar = one year. Y-axis scaled to peak year (12 patents).

3
26
9
27
12
31
6
32
3
33
3
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Linzess
LINACLOTIDE
 AbbVie 30 68 — 2026-08-30
Amitiza
LUBIPROSTONE
 Sucampo Pharma Llc 6 63 — 2027-01-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7304036 Linzess method of use 85 2026-08-30
7304036 Linzess method of use 85 2026-08-30
7304036 Linzess method of use 80 2026-08-30
7304036 Linzess other 80 2027-02-28
7304036 Linzess other 80 2027-02-28
7304036 Linzess other 80 2027-02-28
8748573 Linzess method of use 73 2031-10-30
8748573 Linzess method of use 73 2031-10-30
8933030 Linzess method of use 68 2031-02-17
8933030 Linzess method of use 68 2031-02-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10675325 Linzess formulation 48 2031-08-11
8933030 Linzess formulation 48 2031-02-17
8802628 Linzess formulation 53 2031-10-30
8802628 Linzess formulation 53 2031-10-30
8026393 Amitiza formulation 60 2027-10-25
8026393 Amitiza formulation 60 2027-10-25
9708371 Linzess other 62 2034-02-16
9708371 Linzess other 62 2034-02-16
9708371 Linzess other 62 2034-02-16
9708371 Linzess method of use 62 2033-08-16

Related